0001193125-23-195360.txt : 20230727 0001193125-23-195360.hdr.sgml : 20230727 20230727075558 ACCESSION NUMBER: 0001193125-23-195360 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230727 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230727 DATE AS OF CHANGE: 20230727 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HCA Healthcare, Inc. CENTRAL INDEX KEY: 0000860730 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 273865930 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11239 FILM NUMBER: 231115329 BUSINESS ADDRESS: STREET 1: ONE PARK PLZ CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6153449551 MAIL ADDRESS: STREET 1: ONE PARK PLAZA CITY: NASHVILLE STATE: TN ZIP: 37203 FORMER COMPANY: FORMER CONFORMED NAME: HCA Holdings, Inc. DATE OF NAME CHANGE: 20101126 FORMER COMPANY: FORMER CONFORMED NAME: HCA INC/TN DATE OF NAME CHANGE: 20010627 FORMER COMPANY: FORMER CONFORMED NAME: HCA THE HEALTHCARE CO DATE OF NAME CHANGE: 20010419 8-K 1 d536904d8k.htm FORM 8-K Form 8-K
false 0000860730 0000860730 2023-07-27 2023-07-27

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 27, 2023

 

 

HCA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-11239   27-3865930

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

One Park Plaza, Nashville,

Tennessee

   37203
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (615) 344-9551

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class

   

Trading

Symbol(s)

   

Name of each exchange

on which registered

Common Stock, $.01 par value per share    HCA    New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

 

 

 

Item 2.02. Results of Operations and Financial Condition.

On July 27, 2023, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the second quarter ended June 30, 2023, the text of which is set forth as Exhibit 99.1.

Item 7.01. Regulation FD Disclosure.

On July 27, 2023, the Company issued a press release announcing, among other matters, its results of operations for the second quarter ended June 30, 2023, the text of which is set forth as Exhibit 99.1.

Item 8.01. Other Events.

On July 27, 2023, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.60 per share of the Company’s common stock. The dividend will be paid on September 29, 2023 to stockholders of record at the close of business on September 15, 2023.

Item 9.01. Financial Statements and Exhibits.

 

(d)

Exhibits:

 

Exhibit 99.1    Press Release, dated July 27, 2023
Exhibit 104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

HCA HEALTHCARE, INC.
 

/s/ William B. Rutherford

 

William B. Rutherford

Executive Vice President and Chief Financial Officer

Date: July 27, 2023

EX-99.1 2 d536904dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO                                                 FOR IMMEDIATE RELEASE

 

           
INVESTOR CONTACT:       MEDIA CONTACT:
Frank Morgan       Harlow Sumerford
615-344-2688       615-344-1851

HCA HEALTHCARE REPORTS SECOND QUARTER 2023 RESULTS

RAISES 2023 GUIDANCE

NASHVILLE, Tenn., July 27, 2023 – HCA Healthcare, Inc. (NYSE:HCA), today announced financial and operating results for the second quarter ended June 30, 2023.

Key second quarter metrics (all percentage changes compare 2Q 2023 to 2Q 2022 unless otherwise noted):

 

  ●  

Revenues totaled $15.861 billion

  ●  

Net income attributable to HCA Healthcare, Inc. totaled $1.193 billion, or $4.29 per diluted share

  ●  

Adjusted EBITDA totaled $3.056 billion

  ●  

Cash flows from operating activities totaled $2.475 billion

  ●  

Same facility admissions increased 2.2 percent and same facility equivalent admissions increased 3.7 percent

“The company produced solid results in the second quarter driven by continued strong demand for our services and good execution by our teams. I want to thank our colleagues for their dedication and great work,” said Sam Hazen, Chief Executive Officer of HCA Healthcare.

Revenues in the second quarter of 2023 increased to $15.861 billion, compared to $14.820 billion in the second quarter of 2022. Net income attributable to HCA Healthcare, Inc. totaled $1.193 billion, or $4.29 per diluted share, compared to $1.155 billion, or $3.90 per diluted share, in the second quarter of 2022. The second quarter of 2022 results included losses on sales of facilities of $32 million, or $0.11 per diluted share, and losses on retirement of debt of $78 million, or $0.20 per diluted share.

For the second quarter of 2023, Adjusted EBITDA totaled $3.056 billion, compared to $3.042 billion in the second quarter of 2022. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.

Same facility admissions increased 2.2 percent and same facility equivalent admissions increased 3.7 percent in the second quarter of 2023, compared to the prior year period. Same facility emergency room visits increased 3.7 percent in the second quarter of 2023, compared to the prior year period. Same facility inpatient surgeries increased 1.8 percent while same facility outpatient surgeries increased 3.3 percent in the second quarter of 2023, compared to the same period of 2022. Same facility revenue per equivalent admission increased 2.4 percent in the second quarter of 2023, compared to the second quarter of 2022.

 

1

Six Months Ended June 30, 2023

Revenues for the six months ended June 30, 2023 totaled $31.452 billion, compared to $29.765 billion in the same period of 2022. Net income attributable to HCA Healthcare, Inc. was $2.556 billion, or $9.14 per diluted share, compared to $2.428 billion, or $8.05 per diluted share, for the first six months of 2022. Results for the six months ended June 30, 2023 include losses on sales of facilities of $14 million, or $0.08 per diluted share. Results for the six months ended June 30, 2022 included losses on sales of facilities of $22 million, or $0.08 per diluted share, and losses on retirement of debt of $78 million, or $0.20 per diluted share.

Balance Sheet and Cash Flows from Operations

As of June 30, 2023, HCA Healthcare, Inc.’s balance sheet reflected cash and cash equivalents of $862 million, total debt of $38.932 billion, and total assets of $53.594 billion. During the second quarter of 2023, capital expenditures totaled $1.241 billion, excluding acquisitions. Cash flows provided by operating activities in the second quarter totaled $2.475 billion, compared to $1.630 billion in the second quarter of 2022.

During the second quarter of 2023, the Company repurchased 3.3 million shares of its common stock at a cost of $915 million. The Company had $2.825 billion remaining under its repurchase authorization as of June 30, 2023. As of June 30, 2023, the Company had $6.875 billion of availability under its credit facilities.

Dividend

HCA today announced that its Board of Directors declared a quarterly cash dividend of $0.60 per share on the Company’s common stock. The dividend will be paid on September 29, 2023 to stockholders of record at the close of business on September 15, 2023.

The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company’s financial condition and results of operations and contractual restrictions. Future dividends are expected to be funded by cash balances and future cash flows from operations.

2023 Revised Guidance

The 2023 guidance ranges for the year have been revised from our first quarter release as follows:

 

    

Previous 2023 Guidance Range

as of April 21, 2023

   

2023 Guidance Range

as of July 27, 2023

Revenues    $62.5 to $64.5 billion    $63.25 to $64.75 billion
Net Income Attributable to HCA Healthcare, Inc.    $4.750 to $5.160 billion    $4.900 to $5.255 billion
Adjusted EBITDA    $12.1 to $12.7 billion    $12.3 to $12.8 billion
EPS (diluted)    $17.25 to $18.55 per diluted share    $17.70 to $18.90 per diluted share

 

2

Capital expenditures for 2023, excluding acquisitions, are estimated to be approximately $4.7 billion compared to $4.6 billion previously.

The Company’s 2023 guidance contains a number of assumptions, including, among others, the Company’s current expectations regarding the impact of the COVID-19 pandemic, patient volumes and payor mix as well as general economic conditions, including inflation, and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.

Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to HCA Healthcare, Inc. to forecasted Adjusted EBITDA is included in this release.

The Company’s guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company’s “Forward-Looking Statements.”

Earnings Conference Call

HCA Healthcare will host a conference call for investors at 9:00 a.m. Central Daylight Time today. All interested investors are invited to access a live audio broadcast of the call via webcast. The broadcast also will be available on a replay basis beginning this afternoon. The webcast can be accessed through the Company’s Investor Relations web page at https://investor.hcahealthcare.com/events-and-presentations/default.aspx.

About the Company

As of June 30, 2023, HCA operated 182 hospitals and approximately 2,300 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the United Kingdom.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include statements that do not relate solely to historical or current facts. Forward-looking statements can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) changes in or related to general economic conditions nationally and regionally in our markets, including inflation and economic and business conditions (and the impact thereof on the economy, financial markets and banking industry); changes in revenues due to declining patient volumes; changes in payer mix (including increases in uninsured and underinsured patients); potential increased expenses related to labor, supply chain or other expenditures; workforce disruptions; and supply shortages and disruptions, (2) the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, (3) the impact of current and future federal and state health reform initiatives and possible changes to other federal, state or local laws and regulations affecting the health care industry, including, but not limited to, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “Affordable Care Act”), additional changes to the Affordable Care Act,

 

3

its implementation, or interpretation (including through executive orders and court challenges), and proposals to expand coverage of federally-funded insurance programs as an alternative to private insurance or establish a single-payer system (such reforms often referred to as “Medicare for All”), (4) the effects related to the implementation of sequestration spending reductions required under the Budget Control Act of 2011, related legislation extending these reductions and those required under the Pay-As-You-Go Act of 2010 as a result of the federal budget deficit impact of the American Rescue Plan Act of 2021, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (5) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (6) the ability to achieve operating and financial targets, and attain expected levels of patient volumes and control the costs of providing services, (7) possible changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs or Medicaid waiver programs, that may impact reimbursements to health care providers and insurers and the size of the uninsured or underinsured population, (8) personnel-related capacity constraints, increases in wages and the ability to attract, utilize and retain qualified management and other personnel, including affiliated physicians, nurses and medical and technical support personnel, (9) the highly competitive nature of the health care business, (10) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (11) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (12) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (13) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (14) changes in accounting practices, (15) developments related to COVID-19, including, without limitation, the length and severity of COVID-19-related impacts and the spread of virus strains with new epidemiological characteristics; the volume of canceled or rescheduled procedures and the volume and acuity of COVID-19 patients cared for across our health systems; and measures we are taking to respond to COVID-19, (16) the emergence of and effects related to pandemics, epidemics and infectious diseases, (17) future divestitures which may result in charges and possible impairments of long-lived assets, (18) changes in business strategy or development plans, (19) delays in receiving payments for services provided, (20) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (21) the impact of known and unknown government investigations, litigation and other claims that may be made against us, (22) the impact of actual and potential cybersecurity incidents or security breaches, including the data security incident disclosed in July 2023, (23) our ongoing ability to demonstrate meaningful use of certified electronic health record (“EHR”) technology and the impact of interoperability requirements, (24) the impact of natural disasters, such as hurricanes and floods, physical risks from climate change or similar events beyond our control, (25) changes in U.S. federal, state, or foreign tax laws including interpretive guidance that may be issued by taxing authorities or other standard setting bodies, and (26) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2022 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All references to “Company,” “HCA” and “HCA Healthcare” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

 

4

HCA Healthcare, Inc.

Condensed Consolidated Comprehensive Income Statements

Second Quarter

Unaudited

(Dollars in millions, except per share amounts)

 

     2023        2022    
    

Amount

  

Ratio

       

Amount

  

Ratio

    

Revenues

      $15,861       100.0    

%

      $14,820       100.0    

%

Salaries and benefits

      7,277       45.9          6,792       45.8    

Supplies

      2,478       15.6          2,301       15.5    

Other operating expenses

      3,043       19.2          2,693       18.3    

Equity in losses (earnings) of affiliates

      7       -          (8 )       (0.1 )    

Depreciation and amortization

      763       4.8          738       5.0    

Interest expense

      485       3.1          434       2.9    

Losses (gains) on sales of facilities

      (1 )       -          32       0.2    

Losses on retirement of debt

      -       -          78       0.5    
  

 

 

 

     

 

 

 

  
     14,052       88.6           13,060       88.1    
  

 

 

 

     

 

 

 

  

Income before income taxes

      1,809       11.4          1,760       11.9    

Provision for income taxes

      397       2.5          381       2.6    
  

 

 

 

     

 

 

 

  

Net income

      1,412       8.9          1,379       9.3    

Net income attributable to noncontrolling interests

      219       1.4          224       1.5    
  

 

 

 

     

 

 

 

  

Net income attributable to HCA Healthcare, Inc.

      $1,193       7.5          $1,155       7.8    
  

 

 

 

     

 

 

 

  

Diluted earnings per share

      $4.29            $3.90      

Shares used in computing diluted earnings per share (millions)

      278.198            296.061      

Comprehensive income attributable to HCA Healthcare, Inc.

      $1,207            $1,087      
  

 

 

 

       

 

 

 

    

 

5

HCA Healthcare, Inc.

Condensed Consolidated Comprehensive Income Statements

For the Six Months Ended June 30, 2023 and 2022

Unaudited

(Dollars in millions, except per share amounts)

 

     2023        2022    
    

Amount

  

Ratio

       

Amount

  

Ratio

    

Revenues

      $31,452       100.0    

%

      $29,765       100.0    

%

Salaries and benefits

      14,361       45.7          13,731       46.1    

Supplies

      4,901       15.6          4,622       15.5    

Other operating expenses

      5,937       18.8          5,445       18.4    

Equity in losses (earnings) of affiliates

      25       0.1          (19 )      (0.1 )   

Depreciation and amortization

      1,519       4.8          1,470       4.9    

Interest expense

      964       3.1          842       2.8    

Losses on sales of facilities

      14       -          22       0.1    

Losses on retirement of debt

      -       -          78       0.3    
  

 

 

 

     

 

 

 

  
     27,721       88.1          26,191       88.0    
  

 

 

 

     

 

 

 

  

Income before income taxes

      3,731       11.9          3,574       12.0    

Provision for income taxes

      776        2.5           730        2.4     
  

 

 

 

     

 

 

 

  

Net income

      2,955       9.4          2,844       9.6    

Net income attributable to noncontrolling interests

      399       1.3          416       1.4    
  

 

 

 

     

 

 

 

  

Net income attributable to HCA Healthcare, Inc.

      $2,556       8.1          $2,428       8.2    
  

 

 

 

     

 

 

 

  

Diluted earnings per share

      $9.14            $8.05      

Shares used in computing diluted earnings per share (millions)

      279.573            301.690      

Comprehensive income attributable to HCA Healthcare, Inc.

      $2,590            $2,317      
  

 

 

 

       

 

 

 

    

 

6

HCA Healthcare, Inc.

Condensed Consolidated Balance Sheets

Unaudited

(Dollars in millions)

 

           June 30,               March 31,         December 31,
     2023   2023   2022

ASSETS

       

Current assets:

       

Cash and cash equivalents

      $862       $842       $908  

Accounts receivable

      8,713       8,657       8,891  

Inventories

      2,050       2,085       2,068  

Other

      2,263       1,957       1,776  
  

 

 

 

  

 

 

 

  

 

 

 

     13,888       13,541       13,643  

Property and equipment, at cost

      56,667       55,463       54,757  

Accumulated depreciation

      (30,023 )      (29,410 )      (29,182 ) 
  

 

 

 

  

 

 

 

  

 

 

 

     26,644       26,053       25,575  

Investments of insurance subsidiaries

      384       390       381  

Investments in and advances to affiliates

      731       786       823  

Goodwill and other intangible assets

      9,641       9,590       9,653  

Right-of-use operating lease assets

      2,110       2,032       2,065  

Other

      196       319       298  
  

 

 

 

  

 

 

 

  

 

 

 

     $53,594       $52,711       $52,438  
  

 

 

 

  

 

 

 

  

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

       

Current liabilities:

       

Accounts payable

      $3,823       $3,769       $4,239  

Accrued salaries

      1,776       1,565       1,712  

Other accrued expenses

      3,551       3,316       3,581  

Long-term debt due within one year

      2,395       2,378       370  
  

 

 

 

  

 

 

 

  

 

 

 

     11,545       11,028       9,902  

Long-term debt, less debt issuance costs and discounts of $349, $295 and $301

      36,537       36,478       37,714  

Professional liability risks

      1,554       1,565       1,528  

Right-of-use operating lease obligations

      1,806       1,716       1,752  

Income taxes and other liabilities

      1,691       1,692       1,615  

Stockholders’ equity (deficit):

       

Stockholders’ deficit attributable to HCA Healthcare, Inc.

      (2,303 )      (2,495 )      (2,767 ) 

Noncontrolling interests

      2,764       2,727       2,694  
  

 

 

 

  

 

 

 

  

 

 

 

     461       232       (73 ) 
  

 

 

 

  

 

 

 

  

 

 

 

     $53,594       $52,711       $52,438  
  

 

 

 

  

 

 

 

  

 

 

 

 

7

HCA Healthcare, Inc.

Condensed Consolidated Statements of Cash Flows

For the Six Months Ended June 30, 2023 and 2022

Unaudited

(Dollars in millions)

 

         2023           2022    

Cash flows from operating activities:

     

Net income

      $2,955       $2,844  

Adjustments to reconcile net income to net cash provided by operating activities:

     

Increase (decrease) in cash from operating assets and liabilities:

     

Accounts receivable

      306       (547 ) 

Inventories and other assets

      (301 )      (462 ) 

Accounts payable and accrued expenses

      (505 )      (818 ) 

Depreciation and amortization

      1,519       1,470  

Income taxes

      3       121  

Losses on sales of facilities

      14       22  

Losses on retirement of debt

      -       78  

Amortization of debt issuance costs and discounts

      17       15  

Share-based compensation

      133       171  

Other

      137       81  
  

 

 

 

  

 

 

 

Net cash provided by operating activities

      4,278       2,975  
  

 

 

 

  

 

 

 

Cash flows from investing activities:

     

Purchase of property and equipment

      (2,438 )      (1,941 ) 

Acquisition of hospitals and health care entities

      (124 )      (116 ) 

Sales of hospitals and health care entities

      172       20  

Change in investments

      (16 )      (2 ) 

Other

      (2 )      (11 ) 
  

 

 

 

  

 

 

 

Net cash used in investing activities

      (2,408 )      (2,050 ) 
  

 

 

 

  

 

 

 

Cash flows from financing activities:

     

Issuances of long-term debt

      3,218       5,966  

Net change in revolving credit facilities

      (1,840 )      930  

Repayment of long-term debt

      (608 )      (2,690 ) 

Distributions to noncontrolling interests

      (342 )      (333 ) 

Payment of debt issuance costs

      (30 )      (53 ) 

Payment of dividends

      (339 )      (337 ) 

Repurchase of common stock

      (1,761 )      (4,783 ) 

Other

      (221 )      (201 ) 
  

 

 

 

  

 

 

 

Net cash used in financing activities

      (1,923 )      (1,501 ) 
  

 

 

 

  

 

 

 

Effect of exchange rate changes on cash and cash equivalents

      7       (17 ) 
  

 

 

 

  

 

 

 

Change in cash and cash equivalents

      (46 )      (593 ) 

Cash and cash equivalents at beginning of period

      908       1,451  
  

 

 

 

  

 

 

 

Cash and cash equivalents at end of period

      $862       $858  
  

 

 

 

  

 

 

 

Interest payments

      $925       $777  

Income tax payments, net

      $773       $609  

 

8

HCA Healthcare, Inc.

Operating Statistics

 

     Second Quarter      For the Six Months
Ended June 30,		  
    

2023

       

2022

     

2023

       

2022

  

Operations:

                

Number of Hospitals

      182          182        182          182  

Number of Freestanding Outpatient Surgery Centers*

      126          126        126          126  

Licensed Beds at End of Period

      49,063          48,979        49,063          48,979  

Weighted Average Beds in Service

      41,802          41,930        41,743          41,875  

Reported:

                

Admissions

      522,996          515,113        1,048,231          1,022,069  

% Change

      1.5%             2.6%       

Equivalent Admissions

      938,834          902,757        1,855,369          1,762,047  

% Change

      4.0%             5.3%       

Revenue per Equivalent Admission

    $ 16,894        $ 16,417      $ 16,952        $ 16,892  

% Change

      2.9%             0.4%       

Inpatient Revenue per Admission

    $ 17,689        $ 16,727      $ 17,759        $ 17,207  

% Change

      5.8%             3.2%       

Patient Days

      2,558,563          2,571,328        5,196,466          5,253,046  

% Change

      -0.5%             -1.1%       

Equivalent Patient Days

      4,594,604          4,510,739        9,197,745          9,056,251  

% Change

      1.9%             1.6%       

Inpatient Surgery Cases

      132,447          130,961        262,907          257,841  

% Change

      1.1%             2.0%       

Outpatient Surgery Cases

      263,601          258,182        519,572          505,603  

% Change

      2.1%             2.8%       

Emergency Room Visits

      2,294,205          2,223,999        4,546,874          4,280,388  

% Change

      3.2%             6.2%       

Outpatient Revenues as a
Percentage of Patient Revenues

      39.8%          38.9%        38.7%          38.1%  

Average Length of Stay (days)

      4.892          4.992        4.957          5.140  

Occupancy**

      71.1%          71.0%        72.6%          72.8%  

Same Facility:

                

Admissions

      522,363          511,188        1,047,610          1,014,289  

% Change

      2.2%             3.3%       

Equivalent Admissions

      928,239          895,090        1,843,794          1,745,591  

% Change

      3.7%             5.6%       

Revenue per Equivalent Admission

    $ 16,780        $ 16,385      $ 16,884        $ 16,881  

% Change

      2.4%             0.0%       

Inpatient Revenue per Admission

    $ 17,746        $ 16,702      $ 17,784        $ 17,179  

% Change

      6.3%             3.5%       

Inpatient Surgery Cases

      132,286          129,922        262,757          255,816  

% Change

      1.8%             2.7%       

Outpatient Surgery Cases

      260,478          252,170        514,641          494,076  

% Change

      3.3%             4.2%       

Emergency Room Visits

      2,290,580          2,208,160        4,543,249          4,250,515  

% Change

      3.7%             6.9%       

 

*

Excludes freestanding endoscopy centers (22 centers at June 30, 2023 and 21 centers at June 30, 2022).

**

Reflects the rate of occupancy (patient days and observations) based on weighted average beds in service.

 

9

HCA Healthcare, Inc.

Supplemental Non-GAAP Disclosures

Operating Results Summary

(Dollars in millions, except per share amounts)

 

                  For the Six Months
     Second Quarter        Ended June 30,
    

2023

  

2022

       

2023

  

2022

Revenues

      $15,861       $14,820          $31,452       $29,765  

Net income attributable to HCA Healthcare, Inc.

      $1,193       $1,155          $2,556       $2,428  

Losses (gains) on sales of facilities (net of tax)

      -       32          22       24  

Losses on retirement of debt (net of tax)

      -       60          -       60  
  

 

 

 

  

 

 

 

     

 

 

 

  

 

 

 

Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities
and losses on retirement of debt (a)

      1,193       1,247            2,578       2,512  

Depreciation and amortization

      763       738          1,519       1,470  

Interest expense

      485       434          964       842  

Provision for income taxes

      396        399           768        746   

Net income attributable to noncontrolling interests

      219       224          399       416  
  

 

 

 

  

 

 

 

     

 

 

 

  

 

 

 

Adjusted EBITDA (a)

      $3,056       $3,042          $6,228       $5,986  
  

 

 

 

  

 

 

 

     

 

 

 

  

 

 

 

Adjusted EBITDA margin (a)

      19.3%       20.5%          19.8%       20.1%  

Diluted earnings per share:

            

Net income attributable to HCA Healthcare, Inc.

      $4.29       $3.90          $9.14       $8.05  

Losses (gains) on sales of facilities

      -       0.11          0.08       0.08  

Losses on retirement of debt

      -       0.20          -       0.20  
  

 

 

 

  

 

 

 

     

 

 

 

  

 

 

 

Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of
facilities and losses on retirement of debt (a)

      $4.29       $4.21          $9.22       $8.33  
  

 

 

 

  

 

 

 

     

 

 

 

  

 

 

 

Shares used in computing diluted earnings per share (millions)

      278.198       296.061          279.573       301.690  

 

 

(a)

Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles (“GAAP”). We believe net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health care facilities and their management teams.

 

 

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that losses (gains) on sales of facilities and losses on retirement of debt will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies.

 

 

Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.

 

10

HCA Healthcare, Inc.

Supplemental Non-GAAP Disclosures

2023 Operating Results Forecast

(Dollars in millions, except per share amounts)

 

     For the Year Ending
     December 31, 2023
    

Low

  

High

Revenues

      $63,250       $64,750  

Net income attributable to HCA Healthcare, Inc. (a)

      $4,900       $5,255  

Depreciation and amortization

      3,070       3,100  

Interest expense

      1,950       1,970  

Provision for income taxes

      1,535       1,610  

Net income attributable to noncontrolling interests

      845       865  
  

 

 

 

  

 

 

 

Adjusted EBITDA (a) (b)

          $12,300            $12,800   
  

 

 

 

  

 

 

 

Diluted earnings per share:

     

Net income attributable to HCA Healthcare, Inc.

      $17.70       $18.90  

Shares used in computing diluted earnings per share (millions)

      278.000       278.000  

The Company’s forecasted guidance range is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks.

 

 

(a)

The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy.

 

(b)

Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles (“GAAP”). We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to review and assess operating performance of its health care facilities and their management teams.

 

 

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA is utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry.

 

 

Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.

 

11

EX-101.SCH 3 hca-20230727.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 hca-20230727_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 hca-20230727_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g536904g0727032741453.jpg GRAPHIC begin 644 g536904g0727032741453.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#BM:\:^*8] M=U"./Q%JB(MS(%5;IP QX !XKW_ .%&HWNJ?#RPN[^ZFNKAGE#2S.68@.P& M2?:OF/7?^1@U+_KZE_\ 0C7TG\&?^28Z=_UTF_\ 1C5U5DN4YZ3?,=]1117* M=!\A7/CCQ6+J8#Q)JH <\"[<=_K7TE\-+VZU'X>:1=WMQ+<7$B/OEE8LS8D8 M#)/7@"OD^Z_X^YO^NC?SKZH^%'_),=$_ZYR?^C'KJK)*)STF^8Z/6];T_P / M:5-J6IW"PVT0Y)ZL>R@=R?2OGWQ5\;->U>9X=&/]EV6<*5P9F'J6[?A^9K/^ M+/C&7Q-XJFM(93_9NGN885!X=APS_B>![ >IK/\ ?@"_P#'&HLD3_9[" C[ M1VAL+V4MSBO!7QPN4N(K'Q4%EA8[1?1I MAD_WU'!'N,'ZU[K%+'<0I-#(LD4BAD=#D,#T(/I7QWXH\,:AX2UN72]00;U^ M:.1?NRH>C+[?UR*]E^!&O:G=Z9=Z/=03R65J-]M._$ \,>#=1U)6VSK'Y<'_71N%_+.?PKHZ\%^/OB'SK^P\/0 MO\D"_:9P/[[<*/P&3_P*LJ<>:5C2;M&YYO\ \)SXL_Z&35O_ ,?_&O1_@WX MZU.Z\4RZ1K&IW-VEY$3 ;F4N5D7G STRN[\A7GOA?P?=^)['6KJW)"Z;:&? M7.]L\)^*AS^%8^E:C/I&K6FHVQQ-:S+*GU!SCZ5URBI)HYDVFF?:M%5-,U"# M5M+M=0MFS#-K+:;!,\4$.T,$.-Y(!Y M]N:U?&]Q-!X#-8FUC1-]R=TT+^6S_ M -X8!!^O/Z5T5<-\-KF'[!=VWF+YWF[]F>2,8S^E=S7I82;G1BVSQ,PIJGB9 MQ2L@HHHKH.,^+M=_YO^OJ7_T(UZ;X$^+VF^$_"=MH]QIEU/+"SL9(W4 [ MF+=_K7F6N_\ (P:E_P!?4O\ Z$:Z'0/ACXF\2Z1%JFFV\#VLI8(SSJI.#@\' MW%=TE%KWCDBVGH>H?\-!:/\ ] 6^_P"^TH_X:"T?_H"WW_?:5P7_ I/QI_S MZ6O_ ($K1_PI/QI_SZ6W_@2M9\E(OFJ'GTK^9,\F,;F)Q7TOX-OVTOX$Q7Z' M#V]A<2*?]H-(1^M?,[J4=D8893@U]'>'K=[K]G=H8QEVTVYP/4AI#3K;+U%2 MW9\X$DG)Y)KZW^'6BQ:%X#TJV1 LDL*W$Q[L[C<<_3('T KY'[U]D^$[R/4/ M"&CW41!62SB/T.T C\#D4J^R'1W-BBBBN4Z#$\0>$=$\4/:-J]BMR;5RT>6( MZ]0<=1TX]JUK:V@L[>.WMH8X88QA(XU"JH] !4M%.[M85D17%Q%:6TMS.X2& M%#(['HJ@9)_*OC?Q)K,OB'Q'?ZM-G=WYM+&VNA9Q@?-$IQ(2,DY';MCVKE#H'B C!L+P@_],VKL_$W MBW5-"U5K=+2W:!E#1.ZL2PQSW]3N M?5X1XJ-&/LJ<;6[D&B>"[R>Y6?5(_LME'\TAE."P';V^IKI+G4=+\90W6CQR M>5+&VZW=NCD=Q^O'H:I6/B^T\1*=)UFV6);@A5DC8@;L\?3G'-,L_"-MH%S< M:GJTVZUM6#0!3RYSP3[]./7VZW345&U'6+^*_P#6AG6E*4W+$^[-?"E^G=]S MFY_"FNVDY06,S$'AXAN!_$41Z+XCBA!D>OEFZ_X^YO^NC?SKZH^%'_),=$_ZYR? M^C'KJK_"<]+XCYM\7^'IO"_BB^TJ56"Q2$PL?XXSRI_+]XIQ:J1LQ-.$KH^SHY$EC62- MU=&&593D$>QJ"_U"STNSDN[^YBMK>,9:25@H%?'.G^(=:TI=FGZM?6J?W89V M0?D#4-_JVHZJX?4+^ZNV'0SS,^/S-1[#7>(=?A;1+JXM-/L M6/V=XV*/(_=SCIZ >GU->B_"#QMXD\5-=6^JQQ3VMI&/]-V[7+D\*<<-QDYX MZ<]:\8\)>!]9\8WRPZ?;LML&Q+=2 B.,?7N?8(?[;\=36T3[K;3E^S)@\;QRY_/ MC_@(KF]$\&>(O$=H]UI&ERW4"/Y;2*5 #8!QR1V(_.L2622XG>61B\DC%F8] M6)ZFOKKP%H'_ C7@K3=.9-LXC\V?U\QN6_+./PJYR]G%)$QCSRNSY_TOX.^ M,=0O$AGTX64)/SS3RKA1] 237N][X'L_^%:R^$[4;D6V*1.PY,H.X.?J_/XU MUM%<\JLI&T::1\0.CPRLC@HZ-@@\$$5]=> O$ \3>"].U%GW3^7Y5QZ^8O#? MGU_&OG_XN^'_ .PO'MV\:;;>_'VJ/ XRWWA_WT#^8KJO@'XA\C4K_P /S/\ M)<+]H@!/\:\,!]5P?^ UO57-#F1E3?+*Q[G>6-K?P^5=V\&;#+'YY%+>_R&N;\<6DMOXIFF=3Y<^UT;'!& #^HKH?'O_(L M:;_OK_Z :\:,>15HK^M3Z6<_:2PLWK?_ "1G^!?#UAJD%Q=WL?G;'V(A) '& M2>.M=FGA;0XW#KIT.1TSDC\B:R?A[:36^@R22J5$TQ9,]Q@#/YYKK:[\)1A[ M&+<5<\C,,55^LS49NR\Q JA5 "@8 ':EHHKM/,.8F^'?A"XGDGET"T:21B[ MMM/))R3UKUAXNUF>V MO ^%GN"70KM[C (.X=NU>I>"=%O+#2K>^OM>U+4[B[MHW=;J7=&A(!^08R.O MIV$UI"'-M'+B%P.O Y!QWS7+?" M:'6_%MK-JVI^*M9*6ETJ+;QW&%? #'?G.0:XHAN' _(DU-8?"7P5I\@ MD71UG<=/M$K2#_ODG'Z5UFI61U'3YK075S:^:,>=:OLD3G.5.#BO$ VN:#\; M--T.;Q'JE_9F9'43W#'A[K!!#:PI#;Q1Q1(,*D:A5 M4>P%5M4TFPUNQ:RU*UCN;9B&,<@XR.AK&\=>+?\ A"_#PU7[%]KS.L/E^9LZ M@G.<'TK5T'5/[;T#3]4\GR?M=NDWE[MVW<,XSQFL[-*Y=U>QDQ?#KPA!,DL> M@68=&#*=I.".G>NGKPSXNV6L>%HK2_T_Q5K;0WR MZ,[2:'I[NQ9VMHRS,ZBSLE0'*Y!!QSZ$UT%%/F=K"L@HHH MI#*]Y86M_$([NWCF0'(#C.#[>E-N=.L[R*.*YMXY8XB"BL,@<8JU14N,7NBU M4FK6>PBJ%4*H 4# ' I:**H@**P/$7B1]!N;)#:![>=B);F21ECA&5 R55L M9W<$X''6N/U;XQ0Z;:HZ:+)-.)Y(I8S Q _V35*$GL2Y);G/ M_M#?=\/?6X_]IUWNB^._"D&A:?%+X@T])$MHU93,,@A1D5P7[0W3P]];C_VG M7INA^']%D\/Z:[Z18,S6L19C;(23L'M6CM[-7(5^=V.=\<^-?#%_X&UFUM-= ML9KB6U98XTF!+'T K&^ #-5DD8(B7I9F8X C7)-=/X^T/2+?P#KP;A1C!]1D=<\5=2\7>(/AYXKL+'Q#J M":MHM_\ ,$M4U?Q-92"V+&/R['9C=C/1O84-14K/87O-76YI?%#XAS M^#+>SMK"!'O;P,RRR#*1*,#./XCSQ]*K>)[;QKX=\.3:]9>+FOFME$LUO-8Q M(CIW*X&1CKCT[UH^,M=\+^&=/TR+Q!:0ZGJ$2+]E@$"R2%@ "PS]T$C_ /7B MLGQ;/XSUCP-JUW=P66B:>+1W:U.9[F1Q&#^->9>(_^3CM)^L/_H)KI?@4,?#UO>]D_DM< MUXC_ .3CM)^L/_H)IQ5IR2$W>*98^-4'B2+0));V_LI-(>^4001PD2KPQ7+= M^ :W? ]GXV;PWH,L6L:6NE^1"1";9O,\K ^7/]['>H_CQ_R($'_80C_] >NM M\ ?\D^T#_KQB_P#012;_ ':';WS@OV@?^1=TC_K[;_T"M>WC\>>(- LI-'O+ M70;,6T:P+/'YD\V%'S-P0@/8#)QUK(_:!_Y%[2/^OMO_ $"O4=#_ .1?TW_K MUB_] %%[006O)GF_PU\=:]?>*+_PKXG*27ML'*3! IW(<,IVX!'<'';WK4\8 M>.[Z'Q-:^$/#$<,NM7!'FS2C*6P(SR.YV_,?0=CFN1\/?\G'ZI]9O_0!53X> MR-<_'C6Y;HYF#7>W/8B3&!^&15.*O?R)4G:WF='XSU'Q7\/M)M-7D\5?VG)) M<+#):3V,:1OD$D@KRH&WU[UNZY\2(M,^&]GXIALS))>A4A@8_*LA!SN/H-K? M7';-=3KOA[2O$M@+'5[-;FW#AU4DJ58=P001U-9'B27PGX6\(QV^L6MO_9,6 MV.&T:+S-Q'("J>IZG)^I-9IIVTU+::OJ<]I=OXT\1^$H-?L_%QBO+F$S16BV M,0A!Y^3)!/;&35OX6>.[KQEIMY#J4<:ZC8NHD:,;1(K9P<=CE2#^%&DZOXJ\ M4:=#)H.FV?A[1V7$%Q=KYDK)V*1+A0/J<>F:XWX J1JOB3)W$"$%L=?F>J:O M%W)3U5B[\2_%GCCP5?V[1ZI9/97K2& I:J&0*1\K9SG 8<]^>E)XY\5^/],T MVQUNW":=97$@6.T6 2RA<9!F8@A2?[HZ=.HJ#]H;_CW\/_[UQ_*.O:+?_CVB M_P!P?RHNE%.P6;;5SSG5O'^KRS:'X=T>UB7Q+J-O'+<^<#LL]R;FR/4#)P>@ M ZYH\20>./"FA2ZY;^*1JAM0'N;6XLHT1USR5V\C'IGIGFN%TU=7OOCQK2Z= M?PV=]YLZI+/#YHVKP !_NC]*]'U#PQXYU33;JPNO%.G-;W,312 :< 2K#![^ M]-I1L";=S5\,:II'C[P_8:W+IUN\T;$%98PY@D&,@$CZ$?A6U-H>DW,(AGTR MSEB!W!'@4C//."/<_F:Y[X=^"YO ^BW.GS7RW?G7!F#*A4+E5&,9/I785E*U M]"UMJ?/WQ>U67QA/I<>D:1JTD=H)"\CV4B EMN 1G^']:]6\#>)(=9T>UL_ ML-_:75K;1K*EU;L@R %^5CP>1]:**VG%'=3T.&PU&Z MOKFWV((+5V0;NY;&*X7X6W4=CX?U+POKNCZK$FIS%1*+-RF'4(03CY<=<]/R MHHHBER6$W[PGAN]UGX/:O?:=K.FW5UH=Q)O2[MDRH(X#CMR,94D'@?CVLWCZ MZ\5VW]G^"["]-S/\K:C<0;(+5>[9/5@.@_GTHHH:3CSO<:;4N5'&?$_3-5T3 MQ[HGB>:VFU&QM4M_,E"=6C;+!L<+GJ.W)]*ZK6_%D_CGPI?Z=X8T/4+@W%LP MDN+J/RHD&,X!_C<] !W/)Q111O!2[!M)KN9/P<\10Z5HDOA^]L-1BO(YY)F/ MV5BH7:"73;=H@S"R<,P P2 1[]_2B MBJY4I-DW?*D=U\5+.X\6?#1+C2+:XFV3I<^48F60H RGY",Y&[.,=!6=\/\ MXBQQ^'--T230-:FOK5%MS]GMMZ8' ))(QQUS11412<6GT*;:DF9WQLOGUN*S MTG3=.U&XGM+AGF=+1]@^7& V.>O;BN_\->*K.;PBES+::C;FPMXDN(I;.3># M@#Y0!\W([9]\444.*Y4@3?,V>4:/JTUI\9+OQ+-HVKKIL[R .+)RP!7 8C'M M^M:'C#P_K7A?QU#X\\.V4MW9SL)YHE0[D+##AEQD!@2@HHJF[-?<): MIG7VOQN3^*7AKQ5>^#M(O;YFO[NWF MFDNX[:/(A$FTJJ@(J2.@)&&Z'H3114SBN3T'%^\>;^/_"VM^'_ M !S;^.O#EJ]WA@]S;QJ2P(&UN!R59>N.AR:W[/XQZ->PB.'2M8DU'&/L4=MO M?=Z9!Z>_Z444X)3CKT"3<9:=3I_"BZ_)8SWGB%UCN+N4RQ6: $6D>,!-P^\> ,Y/K6_116#=V:H__9 end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Jul. 27, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0000860730
Document Type 8-K
Document Period End Date Jul. 27, 2023
Entity Registrant Name HCA HEALTHCARE, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-11239
Entity Tax Identification Number 27-3865930
Entity Address, Address Line One One Park Plaza
Entity Address, City or Town Nashville
Entity Address, State or Province TN
Entity Address, Postal Zip Code 37203
City Area Code (615)
Local Phone Number 344-9551
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $.01 par value per share
Trading Symbol HCA
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 8 d536904d8k_htm.xml IDEA: XBRL DOCUMENT 0000860730 2023-07-27 2023-07-27 false 0000860730 8-K 2023-07-27 HCA HEALTHCARE, INC. DE 001-11239 27-3865930 One Park Plaza Nashville TN 37203 (615) 344-9551 false false false false Common Stock, $.01 par value per share HCA NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d536904d8k.htm d536904dex991.htm hca-20230727.xsd hca-20230727_lab.xml hca-20230727_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d536904d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "d536904d8k.htm" ] }, "labelLink": { "local": [ "hca-20230727_lab.xml" ] }, "presentationLink": { "local": [ "hca-20230727_pre.xml" ] }, "schema": { "local": [ "hca-20230727.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hca", "nsuri": "http://www.hcahealthcare.com/20230727", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d536904d8k.htm", "contextRef": "duration_2023-07-27_to_2023-07-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d536904d8k.htm", "contextRef": "duration_2023-07-27_to_2023-07-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hcahealthcare.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001193125-23-195360-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-195360-xbrl.zip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end